All In Biotech

Drug Trial Radar · NCT06193200

Evaluate the Neurological Effects of EryDex on Subjects With A-T

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on Subjects With Ataxia Telangiectasia (NEAT)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jun 24, 2024

Primary completion

Dec 17, 2025

Study completion Dec 17, 2025

Sponsor

Lead sponsor
Quince Therapeutics S.p.A.Industry
Sponsor type
Industry
Collaborators
Biotrial
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).

Conditions

  • Ataxia Telangiectasia

Interventions

  • Dexamethasone sodium phosphateDrug

    Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion

  • PlaceboOther

    Placebo encapsulated in autologous erythrocytes and administered via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)Time frame: Baseline to Visit 9 (approximately 6 months)

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence

    Los Angeles, California

  • The Johns Hopkins Hospital, Division of pediatric allergy and immunology

    Baltimore, Maryland

  • Cincinnati Children's Hospital, Division of neurology

    Cincinnati, Ohio

  • UT Health Houston, Department of pediatrics, division of child & adolescent neurology

    Houston, Texas

  • Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology

    Copenhagen, Denmark

  • University Hospital Frankfurt, Pediatric and Adolescent Clinic

    Frankfurt, Germany

  • IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases

    Frankfurt, Germany

  • Spedali Civili di Brescia, Pediatric immunology department

    Brescia, Italy

  • Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health

    Roma, Italy

  • Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening

    Oslo, Norway

  • MedPolonia sp zoo

    Poznan, Poland

  • Instytut "Pomnik-Centrum Zdrowia Dziecka", Immunology clinic

    Warsaw, Poland

  • Hospital Universitari Vall d'Hebron, Department of pediatric neurology

    Barcelona, Spain

  • Hospital Universitario La Paz, Department of pediatric neurology

    Madrid, Spain

  • University Children's Hospital Zürich - Eleonore Foundation

    Zurich, Switzerland

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection

    London, United Kingdom

  • Great Ormond Street Hospital for Children, Zayed Centre for Research

    London, United Kingdom

  • Nottingham Children's Hospital, Queen's Medical Center, Children's neurology

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.